Biotika AS (XBRA:1BSL01AE) Change In Receivables : €0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Biotika AS Change In Receivables?

Biotika AS's change in receivables for the quarter that ended in Jun. 2023 was €0.00 Mil. It means Biotika AS's Accounts Receivable stayed the same from Dec. 2022 to Jun. 2023 .

Biotika AS's change in receivables for the fiscal year that ended in Dec. 2022 was €0.27 Mil. It means Biotika AS's Accounts Receivable declined by €0.27 Mil from Dec. 2021 to Dec. 2022 .

Biotika AS's Accounts Receivable for the quarter that ended in Jun. 2023 was €0.62 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biotika AS's Days Sales Outstanding for the six months ended in Jun. 2023 was 12.20.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biotika AS's liquidation value for the six months ended in Jun. 2023 was €3.87 Mil.

Biotika AS Change In Receivables Historical Data

The historical data trend for Biotika AS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotika AS Change In Receivables Chart

Biotika AS Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

0.04

1.14

1.05

0.04

0.27

Biotika AS Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															0.56	-0.52	-	-	-

Biotika AS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Biotika AS (XBRA:1BSL01AE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biotika AS's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.62	/	9.275	*	91
=	12.20

2. In Ben Graham's calculation of liquidation value, Biotika AS's accounts receivable are only considered to be worth 75% of book value:

Biotika AS's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.422	-	3.566	+	0.75 * 0.62	+	0.5 * 5.09
=	3.87

Biotika AS Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biotika AS's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotika AS (XBRA:1BSL01AE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biotika AS (XBRA:1BSL01AE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slovenskc Lupca 566, Banská Bystrica, SVK, 976 13

Website

https://www.biotika.sk

Biotika AS is a manufacturer of pharmaceutical preparations for the human and veterinary application. It is engaged in the production of Active Pharmaceutical Ingredients (API), contract manufacturing of API, and contract manufacturing of final dosage formulations. It also offers research and development services. It manufacturers Polymyxine B Sulfate and other API for third parties (toll manufacturing) of pharmaceutical quality. Biotika is well known as a reliable manufacturer of high-quality pharmaceutical preparations for the human as well as veterinary application and also as a very important producer of the feed additives for breeding farm animals.

Biotika AS (XBRA:1BSL01AE) Headlines

No Headlines